Celldex Therapeutics Stock
Price
Target price
?
?
-3.800%
-1.16
-3.800%
€38.62
08:07 / Frankfurt
WKN: A2PEAB / Symbol: CLDX / Name: Celldex / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Celldex Therapeutics Stock
Heavy losses for Celldex Therapeutics today as the stock fell by -€1.160 (-3.800%).
Currently there is a rather positive sentiment for Celldex Therapeutics with 15 Buy predictions and 3 Sell predictions.
As a result the target price of 38 € shows a positive potential of 29.34% compared to the current price of 29.38 € for Celldex Therapeutics.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Celldex Therapeutics stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Celldex Therapeutics in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
C******** o* t** e**********
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Celldex Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Celldex Therapeutics | -3.800% | -8.863% | 9.149% | 59.895% | 38.818% | -7.455% | -16.237% |
| Larimar Therapeutics Inc. | -1.750% | 1.852% | 7.143% | 19.565% | -0.602% | 16.197% | -59.756% |
| Northwest Biotherapeutics Inc. | -8.000% | 0.000% | -25.000% | -25.000% | -27.184% | -68.220% | -86.842% |
| Achieve Life Sciences Inc. | 3.700% | 1.887% | 29.808% | 134.783% | 45.946% | 16.379% | -20.000% |
Comments
Celldex Therapeutics (CLDX) had its price target lowered by Wells Fargo & Company from $54.00 to $48.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (CLDX) had its price target lowered by Morgan Stanley from $44.00 to $40.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
Celldex Therapeutics (CLDX) had its price target lowered by Cantor Fitzgerald from $67.00 to $61.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for CLDX provided by MarketBeat
News
Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss
Celldex Therapeutics (NASDAQ:CLDX) said a Phase 2 trial of barzolvolimab in prurigo nodularis did not meet its primary or secondary endpoints, prompting the company to discontinue development of
